Zhao Jinlong, Zhou Guanghui, Yang Junzheng, Pan Jianke, Sha Bangxin, Luo Minghui, Yang Weiyi, Liu Jun, Zeng Lingfeng
The Second Clinical College of Guangzhou University of Chinese Medicine, Guangzhou, China.
Guangdong Provincial Hospital of Chinese Medicine, Guangzhou, China.
Front Nutr. 2023 Jul 27;10:1234756. doi: 10.3389/fnut.2023.1234756. eCollection 2023.
Resveratrol is a natural polyphenol compound that is widely present in herbal medicines such as , , and Catsiatora Linn and is used in traditional Chinese medicine to treat metabolic bone deseases. Animal experiments have shown that resveratrol may have a strong treatment effect against osteoporosis (OP). The purpose of this study was to explore the efficacy of resveratrol in treating OP animal models based on preclinical research data.
This study was completed according to the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines. We searched the PubMed, Embase, Cochrane Library, and China National Knowledge Infrastructure (CNKI) databases from inception to May 8, 2023, to identify animal experiments on the treatment of OP with resveratrol. The effect sizes of bone mineral density (BMD), parameters of micro-CT, serum calcium, phosphorus, alkaline phosphatase (ALP) and osteocalcin were expressed as the mean differences (MDs) and 95% confidence intervals (CIs). RevMan 5.4 software was used for data analysis.
This meta-analysis included a total of 15 animal experiments, including 438 OP rats. The meta-analysis results showed that compared with the control group, resveratrol (<10, 10-25, 40-50, ≥ 60 mg/kg/day) significantly increased femoral and lumbar bone mineral density (BMD) in OP rats ( < 0.05). Resveratrol (<10 mg/kg/day) significantly increased the BMD of the total body (MD = 0.01, 95% CI: 0.01 to 0.01, < 0.001). In terms of improving the parameters related to micro-CT, resveratrol (40-50 mg/kg/day) can increase trabecular thickness and trabecular number and reduce trabecular spacing ( < 0.05). Compared with the control group, resveratrol can reduce the concentration of calcium and phosphorus in serum but has no significant effect on serum ALP and osteocalcin ( > 0.05). The results of subgroup analysis showed that resveratrol increased the whole-body BMD of SD rats ( = 0.002) but did not improve the whole-body BMD of 3-month-old rats ( = 0.17).
Resveratrol can increase BMD in OP rat models, and its mechanism of action may be related to improving bone microstructure and regulating calcium and phosphorus metabolism. The clinical efficacy of resveratrol in the treatment of OP deserves further research.
白藜芦醇是一种天然多酚化合物，广泛存在于虎杖等草药中，在传统中医中用于治疗代谢性骨病。动物实验表明，白藜芦醇可能对骨质疏松症（OP）具有较强的治疗作用。本研究旨在基于临床前研究数据探讨白藜芦醇治疗OP动物模型的疗效。
本研究按照系统评价和Meta分析的首选报告项目（PRISMA）指南完成。我们检索了PubMed、Embase、Cochrane图书馆和中国国家知识基础设施（CNKI）数据库，检索时间从建库至2023年5月8日，以确定白藜芦醇治疗OP的动物实验。骨密度（BMD）、显微CT参数、血清钙、磷、碱性磷酸酶（ALP）和骨钙素的效应大小以平均差（MDs）和95%置信区间（CIs）表示。使用RevMan 5.4软件进行数据分析。
本Meta分析共纳入15项动物实验，包括438只OP大鼠。Meta分析结果显示，与对照组相比，白藜芦醇（<10、10 - 25、40 - 50、≥60mg/kg/天）显著增加了OP大鼠的股骨和腰椎骨密度（BMD）（P<0.05）。白藜芦醇（<10mg/kg/天）显著增加了全身骨密度（MD = 0.01，95%CI：0.01至0.01，P<0.001）。在改善与显微CT相关的参数方面，白藜芦醇（40 - 50mg/kg/天）可增加骨小梁厚度和骨小梁数量，并减少骨小梁间距（P<0.05）。与对照组相比，白藜芦醇可降低血清钙和磷浓度，但对血清ALP和骨钙素无显著影响（P>0.05）。亚组分析结果显示，白藜芦醇增加了SD大鼠的全身骨密度（P = 0.002），但未改善3月龄大鼠的全身骨密度（P = 0.17）。
白藜芦醇可增加OP大鼠模型的骨密度，其作用机制可能与改善骨微结构和调节钙磷代谢有关。白藜芦醇治疗OP的临床疗效值得进一步研究。
